NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Ace Therapeutics' Schizophrenia Animal Model Services for Drug Discovery
TL;DR
Ace Therapeutics' schizophrenia animal model platform gives researchers a competitive edge by accelerating therapeutic target discovery through over 20 distinct, validated preclinical models.
The platform employs four core induction methods including genetic manipulation and drug induction, with detailed protocols for species, age, and experimental parameters to ensure precise model construction.
This advancement accelerates understanding of schizophrenia's neurobiological basis, potentially leading to faster development of therapies for this devastating chronic neuropsychiatric disease.
Ketamine-induced models mimic schizophrenia symptoms by causing NMDAR hypofunction, while genetic knockout models like DISC-1 show reduced brain volume and spatial memory deficits.
Found this article helpful?
Share it with your network and spread the knowledge!
Ace Therapeutics is announcing the commercial launch of its translational mature schizophrenia animal model R&D platform, a set of preclinical capabilities designed to accelerate understanding of schizophrenia's neurobiological basis and expedite therapeutic target discovery.
Preclinical animal models remain indispensable in schizophrenia research because they allow researchers to monitor disease progression more rapidly, investigate structural and molecular changes during pathogenesis, and explore candidate therapeutics.
Ace Therapeutics has built more than 20 distinct schizophrenia animal models based on four core induction methods: developmental intervention, drug induction, brain lesion, and genetic manipulation.
The models are developed using cutting-edge technical approaches including genetic manipulation for protein expression modulation, neurotransmitter regulation, environmental factor intervention, prenatal immune activation, selective breeding, and electrical stimulation/lesioning for brain circuit modification.
Key models include the ketamine-induced model (linked to NMDAR hypofunction), dizocilpine (MK-801)-induced model (disrupts glutamatergic signaling), and genetic knockout models (including DISC-1, Neuregulin1/ErbB4, Dysbindin, and Reelin knockout models).
Ace Therapeutics requires customers to confirm key project details including model species (rat, mouse, or other species), animal weight/age specifications, gender requirements, specific model construction plans, and to provide experimental materials (therapeutic drugs) and detailed experimental protocols.
Ace Therapeutics provides end-to-end support from solution customization to final report delivery, empowering research teams to deepen their understanding of schizophrenia's neurobiological mechanisms and accelerate new therapy development.
This announcement was made on December 25, 2025, as indicated in the press release header.
You can find more information on their website at https://www.acetherapeutics.com/psychiatry/schizophrenia-animal-models.html.
Curated from 24-7 Press Release
